Month: December 2020

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma

Combination Represents One of Allogene’s Three Strategies to Target BCMA for Multiple MyelomaPhase 1 Clinical Trial Expected to Begin in...

error: Content is protected !!